Combined therapeutic use of antibodies and immunoglobulin g-degrading enzymes
AssigneeImmago Biosystems Ltd
InventorsMatthew David Max Crispin, Christopher Neil Scanlan
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions comprising therapeutic antibodies, and uses and methods for increasing the potency of therapeutic antibodies. In particular, the invention provides a composition comprising (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and (ii) a therapeutic antibody, preferably a therapeutic antibody which is resistant to the agent. The therapeutic antibody may be administered to the subject after a set time interval, or the blood of the subject may be treated with the agent prior to administration of the therapeutic antibody.
Claims20
A composition comprising:
- (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, wherein said agent is EndoS, and
- (ii) a therapeutic antibody, wherein said therapeutic antibody is trastuzumab, as a combined preparation for sequential use, in a method of treating breast cancer in a subject, wherein the method comprises the steps:
- (a) administering said agent to the subject;
- and subsequently,
- (b) after a set time interval, administering said therapeutic antibody to the subject.
A composition comprising:
- (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and
- (ii) a therapeutic antibody, preferably a therapeutic antibody which is resistant to the agent.
A therapeutic antibody which is resistant to an agent which reduces Fc receptor binding of endogenous serum antibodies.
Dependencies are inferred from the claim text.